Enliven Therapeutics director Garland J. Scott disposes of $606,719 in common shares
ELVN•Director Garland J. Scott exercised options for 13,000 Enliven Therapeutics shares on Oct. 1, 2026, at $15.47 each, then sold them at a weighted average price of $46.6707. His directly held common stock position fell to zero, and he held 46,372 options after the exercise.
1. Share transactions
Scott exercised options for 13,000 common shares on Oct. 1, 2026, at $15.47 per share and sold the same number that day at a weighted average price of $46.6707. His directly held common stock position fell to zero following the transactions, while he reported holding 46,372 options.
